Economic Burden of Attention-Deficit/Hyperactivity Disorder among Pediatric Patients in the United States
- PMID: 28408002
- DOI: 10.1016/j.jval.2017.01.007
Economic Burden of Attention-Deficit/Hyperactivity Disorder among Pediatric Patients in the United States
Abstract
Objectives: To determine the adjusted incremental total costs (direct and indirect) for patients (aged 3-17 years) with attention-deficit/hyperactivity disorder (ADHD) and the differences in the adjusted incremental direct expenditures with respect to age groups (preschoolers, 0-5 years; children, 6-11 years; and adolescents, 12-17 years).
Methods: The 2011 Medical Expenditure Panel Survey was used as the data source. The ADHD cohort consisted of patients aged 0 to 17 years with a diagnosis of ADHD, whereas the non-ADHD cohort consisted of subjects in the same age range without a diagnosis of ADHD. The annual incremental total cost of ADHD is composed of the incremental direct expenditures and indirect costs. A two-part model with a logistic regression (first part) and a generalized linear model (second part) was used to estimate the incremental costs of ADHD while controlling for patient characteristics and access-to-care variables.
Results: The 2011 Medical Expenditure Panel Survey database included 9108 individuals aged 0 to 17 years, with 458 (5.0%) having an ADHD diagnosis. The ADHD cohort was 4.90 times more likely (95% confidence interval [CI] 2.97-8.08; P < 0.001) than the non-ADHD cohort to have an expenditure of at least $1, and among those with positive expenditures, the ADHD cohort had 58.4% higher expenditures than the non-ADHD cohort (P < 0.001). The estimated adjusted annual total incremental cost of ADHD was $949.24 (95% CI $593.30-$1305.18; P < 0.001). The adjusted annual incremental total direct expenditure for ADHD was higher among preschoolers ($989.34; 95% CI $402.70-$1575.98; P = 0.001) than among adolescents ($894.94; 95% CI $428.16-$1361.71; P < 0.001) or children ($682.71; 95% CI $347.94-$1017.48; P < 0.001).
Conclusions: Early diagnosis and use of evidence-based treatments may address the substantial burden of ADHD.
Keywords: attention-deficit/hyperactivity disorder; children; cost of illness; health care costs.
Copyright © 2017 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
Similar articles
-
Parent-Reported Health Consequences and Relationship to Expenditures in Children with ADHD.Matern Child Health J. 2016 Apr;20(4):915-24. doi: 10.1007/s10995-015-1880-1. Matern Child Health J. 2016. PMID: 26754346
-
Attention-deficit/hyperactivity disorder: increased costs for patients and their families.J Am Acad Child Adolesc Psychiatry. 2003 Dec;42(12):1415-23. doi: 10.1097/00004583-200312000-00008. J Am Acad Child Adolesc Psychiatry. 2003. PMID: 14627876
-
Health care use and costs for children with attention-deficit/hyperactivity disorder: national estimates from the medical expenditure panel survey.Arch Pediatr Adolesc Med. 2002 May;156(5):504-11. doi: 10.1001/archpedi.156.5.504. Arch Pediatr Adolesc Med. 2002. PMID: 11980558
-
Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States.J Am Acad Child Adolesc Psychiatry. 2012 Oct;51(10):990-1002.e2. doi: 10.1016/j.jaac.2012.07.008. Epub 2012 Sep 5. J Am Acad Child Adolesc Psychiatry. 2012. PMID: 23021476 Review.
-
The economic impact of attention-deficit/hyperactivity disorder in children and adolescents.Ambul Pediatr. 2007 Jan-Feb;7(1 Suppl):121-31. doi: 10.1016/j.ambp.2006.08.002. Ambul Pediatr. 2007. PMID: 17261491 Review.
Cited by
-
Dietary phytochemical index and attention-deficit/hyperactivity disorder in Iranian children: a case control study.Eur J Clin Nutr. 2022 Mar;76(3):456-461. doi: 10.1038/s41430-021-00952-z. Epub 2021 Jun 10. Eur J Clin Nutr. 2022. PMID: 34112986
-
Economic burden of attention-deficit/hyperactivity disorder among adults in the United States: a societal perspective.J Manag Care Spec Pharm. 2022 Feb;28(2):168-179. doi: 10.18553/jmcp.2021.21290. Epub 2021 Nov 22. J Manag Care Spec Pharm. 2022. PMID: 34806909 Free PMC article.
-
Alerting network, cognitive flexibility in children with attention deficit hyperactivity disorder and the moderating effect of neuroticism.Medicine (Baltimore). 2023 Oct 13;102(41):e35583. doi: 10.1097/MD.0000000000035583. Medicine (Baltimore). 2023. PMID: 37832046 Free PMC article.
-
Smoking Cessation Is Associated With Lower Indirect Costs.J Occup Environ Med. 2018 Jun;60(6):490-495. doi: 10.1097/JOM.0000000000001302. J Occup Environ Med. 2018. PMID: 29465514 Free PMC article.
-
Elevated risk of attention deficit hyperactivity disorder (ADHD) in Japanese children with higher genetic susceptibility to ADHD with a birth weight under 2000 g.BMC Med. 2021 Sep 24;19(1):229. doi: 10.1186/s12916-021-02093-3. BMC Med. 2021. PMID: 34556092 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical